GlobeNewswire

Centrient Pharmaceuticals to acquire Astral SteriTech, expanding its product portfolio with sterile injectable antibiotic finished dosage forms

Share

Rotterdam, the Netherlands, February 15th, 2021, Feb. 15, 2021 (GLOBE NEWSWIRE) --

  • Further strengthens Centrient Pharmaceuticals’ position as the global business-to-business industry leader in beta-lactam antibiotics
  • Broadens Centrient Pharmaceuticals’ product portfolio with sterile injectable Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms, able to further meet the needs of customers in these segments and become a preferred partner for customers
  • Brings in-house manufacturing capabilities for high-quality sterile antibiotic powder injectable finished dosage forms with two US FDA-approved production lines

Centrient Pharmaceuticals (“Centrient”), the business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins and anti-fungals, today announced the signing of an agreement for the acquisition of Astral SteriTech Private Limited (“Astral SteriTech”), a leading international manufacturer specialised in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens its position as the global business-to-business industry leader in beta-lactam antibiotics.

The acquisition of Astral SteriTech is an important step on Centrient’s journey to become the leading, diversified and fully integrated partner to generics marketers.

The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins. Being close to Centrient’s core products of beta-lactam antibiotics, the acquired product portfolio provides Centrient a diversification opportunity within the attractive growing niche segment of sterile injectable antibiotics.

With the broadened product portfolio, Centrient can further meet the needs of its customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms and become the preferred partner in these segments.

Astral SteriTech has a US FDA-approved manufacturing site with two manufacturing lines and serves customers in highly regulated markets like the United States and other regions such as South Asia.

The transaction is subject to customary regulatory approvals and closing conditions.

Rex Clements, CEO at Centrient said: The acquisition of Astral SteriTech is a significant step forward on the journey we at Centrient have undertaken to become the preferred commercial partner to our customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin antibiotics.

By broadening of our product portfolio and adding advanced manufacturing capabilities, we will strengthen the delivery of our value proposition of Quality, Reliability and Sustainability.

These finished dosage forms are critical medicines in healthcare but face increasing risks of supply shortage. At Centrient, we are committed to ensuring a sustainable supply of these products in healthcare, in line with our purpose to improve lives by being at the centre of sustainable and accessible healthcare.”

Dr. Dushyant Patel, Chairman and Managing Director at Astral SteriTech said: “We are proud that with Astral SteriTech’s core competencies and proven strong track record in sterile injectable Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms, we can contribute to synergize and consolidate Centrient’s antibiotics product portfolio, to support their geographical expansion agenda.

Centrient’s vision and strategies for global success blended with Astral SteriTech’s strong fundamentals in the niche area will not only enhance quality of service to existing clients but will help expand the business horizon.”

For the transaction, Barclays acted as the exclusive financial advisor, and Sidley Austin LLP and Trilegal as legal advisors to Centrient Pharmaceuticals. J.P. Morgan acted as the exclusive financial advisor and Shardul Amarchand Mangaldas & Co as legal advisor to Astral SteriTech.

-----------------------------------------------------------------------------------------------------------------------------------

About Astral SteriTech Private Limited

Astral SteriTech is a leading international contract manufacturer specialized in sterile antibiotic powder injectable finished dosage forms.

Established as Astral Pharmaceutical Industries in 1991 by Dr. Dushyant Patel, current Chairman and Managing Director, and renamed into Astral SteriTech Private Limited in 2012, the company carved its niche as a preferred Contract and Development Manufacturing Organisation in the industry segment of sterile antibiotic injectable formulations. The company has a US FDA-approved manufacturing site with two dedicated manufacturing lines, located in Vadodara, Gujarat, India, and serves customers in high regulated markets like the United States and other regions such as South Asia.

The company’s core competencies include advanced aseptic fill and finish technologies and processes, the highest quality standards supported by its robust Quality System, regulatory services along all product development stages, and extensive product development knowledge.

For more information on Astral SteriTech please visit www.astralsteritech.com.

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals. We produce and sell intermediates, active pharmaceutical ingredients and finished dosage forms.  

We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 2200 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance.  

Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, Egypt, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, a leading global private investment firm. 

For more information please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. E-Mail: alice.beijersbergen@centrient.com.


Forward-looking statements

This press release may contain forward-looking statements with respect to Centrient Pharmaceuticals’ future financial

performance and position. Such statements are based on current expectations, estimates and projections of Centrient and information currently available to the company. Centrient cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Centrient has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is governing.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

SEK CREDIT OPERATION ANNOUNCEMENT1.3.2021 10:30:00 CETPress release

Bid date, 2021-03-01Auction date2021-03-01Settlement date2021-03-01Maturity Date2021-05-31Term13 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-01 Bid date, 2021-03-01Auction date2021-03-01Settlement date2021-03-01Maturity Date2021-08-30Term26 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to e-maileol@riksbank.seOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-03-01 This is a translation of the Swedish version published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language v

IBFD launches Talking Points, a fresh perspective on the latest tax developments1.3.2021 10:00:00 CETPress release

AMSTERDAM, March 01, 2021 (GLOBE NEWSWIRE) -- We are excited to announce the launch of Talking Points today, a brand new service that will provide IBFD users with market-leading commentary and analysis on the latest and hottest developments in international taxation. Talking Points will showcase thought leadership from around the world on key developments, news items and other important international tax topics. IBFD users will benefit from valuable insights, reasoning, opinions and viewpoints putting tax developments in perspective from some of the most prominent leaders in international taxation. Maarten Goudsmit, Publishing Director, IBFD, says, “We are excited to launch this new format. Talking Points will provide the tax community with timely, insightful commentary and analysis of the impact of the latest hot topics on daily practice, from leading industry experts.” To celebrate this launch, we will make the first article on Crossing the Digital Services Tax Divide – But Is It Wor

The Bonduelle Group specifies its mission and enshrines it in its articles of association: We inspire the transition toward a plant-based diet to contribute to people's well-being and planet health1.3.2021 10:00:00 CETPress release

Pressrelease Villeneuve d’Ascq, March 1, 2021 The Bonduelle Group specifies its mission and enshrines it in its articles of association. “We inspire the transition toward a plant-based diet to contribute to people's well-being and planet health”. At the presentation of its first half-year financial results for the 2020-2021 fiscal year on February 26, the Bonduelle Group presented its mission. Submitted to the shareholders' vote at the last Shareholders' Meeting, it was very widely approved (99.91%) and is now enshrined in the company's articles of association. It is intended to guide the group's future strategic choices and reinforces Bonduelle's long-term vision. It reaffirms the company's determination to play an active role in the socio-economic and environmental challenges of today and tomorrow. Towards a more resilient model that creates positive impacts Committed to the B Corp certification process and a founding member of the B Movement Builders, Bonduelle reaffirms its commitm

Net asset value as per February 28, 20211.3.2021 10:00:00 CETPress release

On February 28, 2021, net asset value was SEK 299 per share. The closing price on February 26, 2021, was SEK 300.00 for the Class A shares and SEK 278.90 for the Class C shares. Stockholm, March 1, 2021 AB INDUSTRIVÄRDEN (publ) For further information, please contact: Sverker Sivall, Head of Corporate Communication and Sustainability, tel. +46-8-666 64 00 Submitted for publication on March 1, 2021 at 10:00 a.m. Attachment Substansvarde_210301_eng

Agillic wins international gaming platform provider Multilot as a new client: Personalisation is the name of the game1.3.2021 09:00:00 CETPress release

Press release, Copenhagen, 1 March 2021 Agillic, a leading Danish omnichannel marketing software company, will help Multilot, a multinational SaaS gaming platform provider, build long-lasting customer relationships through automated and personalised communication across the customer lifecycle. Multilot offers a fully compliant turn-key gaming platform as a service (SaaS). They operate games, bingo, lotteries, raffles and games of chance on behalf of humanitarian organisations, associations, media houses and corporate partners. Multilot can manage the entire value chain, including assistance in applying for national gaming licenses, game development, assurance of compliance to laws and regulations, customer support, accounting and reporting to the authorities. Further, the company caretakes the direct communication with end-users. And it is for this purpose Multilot has chosen Agillic. Says Petter Danbolt CEO, Multilot: “Gaming is entertainment and fun, hopes and dreams. When we provide

GOGL – Private placement: issue of New Shares1.3.2021 08:34:35 CETPress release

1 March 2021, Hamilton, Bermuda Reference is made to the stock exchange release by Golden Ocean Group Limited (NASDAQ and OSE: GOGL) (“Golden Ocean” or the "Company”) on 17 February 2021 regarding completion of the private placement of new shares in the Company (the "Private Placement"). The new shares have been legally and validly issued and fully paid, and the Company's issued share capital has been increased to USD 9,924.012.20, divided into 198,480,244 issued shares, each with a nominal value of USD 0.05. The new shares are registered under a separate ISIN pending approval of a listing prospectus by the Financial Supervisory Authority of Norway, and will not be listed or tradable on the Oslo Stock Exchange until the listing prospectus is approved. For further queries, please contact: Ulrik Andersen: Chief Executive Officer, Golden Ocean Management AS +47 22 01 73 53 Peder Simonsen: Chief Financial Officer, Golden Ocean Management AS +47 22 01 73 45